← Back to Calendar

Protagonist Therapeutics Q4 2025 Earnings

Protagonist Therapeutics · $PTGX

Standard Review Earnings

PDUFA Date

February 25, 2026

Time Remaining

27d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + rusfertide REVIVE Phase 3 update

Key Notes

Q4 2025 earnings reported February 25, 2026. Key milestones: REVIVE Phase 3 trial in polycythemia vera ongoing — data expected H2 2026. Rusfertide hepcidin mimetic program on track.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar